WO2015183985A3 - Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations - Google Patents

Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations Download PDF

Info

Publication number
WO2015183985A3
WO2015183985A3 PCT/US2015/032716 US2015032716W WO2015183985A3 WO 2015183985 A3 WO2015183985 A3 WO 2015183985A3 US 2015032716 W US2015032716 W US 2015032716W WO 2015183985 A3 WO2015183985 A3 WO 2015183985A3
Authority
WO
WIPO (PCT)
Prior art keywords
naphthoquinones
phe
lys
arg
aromatic
Prior art date
Application number
PCT/US2015/032716
Other languages
English (en)
Other versions
WO2015183985A2 (fr
Inventor
D. Travis Wilson
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of WO2015183985A2 publication Critical patent/WO2015183985A2/fr
Publication of WO2015183985A3 publication Critical patent/WO2015183985A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour le traitement et/ou la prévention de maladies ou d'états pathologiques, méthodes comprenant l'administration de naphthoquinones, et/ou de dérivés d'originie naturelle ou artificielle, d'analogues, ou de sels pharmaceutiquement acceptables de ceux-ci, seuls ou combinés à un ou plusieurs agents actifs (par ex.., un peptide aromatique-cationique). La présente technologie porte sur des compositions associées à des peptides aromatiques-cationiques liés à des naphtoquinones et sur leurs utilisations. Dans certains modes de réalisation, le peptide aromatique-cationique comprend 2',6'-diméthyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/032716 2014-05-28 2015-05-27 Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations WO2015183985A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003741P 2014-05-28 2014-05-28
US62/003,741 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015183985A2 WO2015183985A2 (fr) 2015-12-03
WO2015183985A3 true WO2015183985A3 (fr) 2016-03-17

Family

ID=54700045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032716 WO2015183985A2 (fr) 2014-05-28 2015-05-27 Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2015183985A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2625740C1 (ru) * 2016-10-10 2017-07-18 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство для лечения ишемии сосудов головного мозга
CN115364221A (zh) * 2022-07-11 2022-11-22 海南医学院第一附属医院 Apelin/APJ通路的上调表达促进剂在百草枯中毒肾损伤药物中的应用
CN115326958B (zh) * 2022-08-11 2023-11-24 北京大学第三医院（北京大学第三临床医学院） 一种辅助预测或诊断肥胖合并高脂血症儿童的标志物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2014022551A1 (fr) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methodes de traitement de l'atherosclerose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022551A1 (fr) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methodes de traitement de l'atherosclerose
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATRITZKY, AR ET AL.: "Efficient Syntheses Of Naphthoquinone-Dipeptides.", SYNTHESIS., vol. 12, 2010, pages 2011 - 2016 *

Also Published As

Publication number Publication date
WO2015183985A2 (fr) 2015-12-03

Similar Documents

Publication Publication Date Title
WO2016004093A3 (fr) Compositions thérapeutiques comprenant des inhibiteurs de la galectine-3 et utilisations de celles-ci
WO2015183963A3 (fr) Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations
WO2015183995A3 (fr) Compositions thérapeutiques comprenant de la frataxine, de la lactoferrine et des enzymes mitochondriales génératrices d'énergie et leurs utilisations
WO2014165607A3 (fr) Formulations peptidiques cationiques aromatiques, compositions et procédés d'utilisation
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu'agents de ciblage de protéines
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
CA3010568A1 (fr) Supports nanofibreux oromumuqueux pour traitement therapeutique
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
WO2015171965A3 (fr) Molécules de fusion dérivées de la toxine cholix pour l'administration par voie orale d'une charge biologiquement active
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
WO2017091767A3 (fr) Formulations de médicaments pour le traitement du cancer
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
WO2015183985A3 (fr) Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
WO2015183984A3 (fr) Compositions thérapeutiques contenant un tocophérol et leurs utilisations
WO2016015798A9 (fr) Composition de film orodispersible, comprenant de l'énalapril pour le traitement de l'hypertension dans une population pédiatrique
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
EP4219534A3 (fr) Procédés de traitement et de prophylatise contre les troubles inflammatoires
MX2018001989A (es) Formulaciones farmaceuticas.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
NZ719321A (en) Storage stable lyophilized tripeptide formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800451

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 15800451

Country of ref document: EP

Kind code of ref document: A2